CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease
By Colin Kellaher
CRISPR Therapeutics and Vertex Pharmaceuticals have won Food and Drug Administration approval of their Casgevy gene therapy for sickle-cell disease, marking the first U.S. green light for a drug using the gene-editing technology known as Crispr.
The FDA on Friday said the approval covers Casgevy for the treatment of sickle-cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises
U.K. regulators last month gave the world's first approval of Casgevy, granting conditional marketing authorization for the treatment of sickle-cell disease and transfusion-dependent beta thalassemia, a pair of inherited blood disorders.
An FDA decision on Casgevy in transfusion-dependent beta thalassemia is due by the end of March.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 08, 2023 11:31 ET (16:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks